Peppelenbosch Noud, Geelkerken Robert H, Soong Chee, Cao Piergiorgio, Steinmetz Oren K, Teijink Joep A W, Lepäntalo Mauri, De Letter Jan, Vermassen Frank E G, DeRose Guy, Buskens Erik, Buth Jaap
Catharina Hospital, University Medical Center, 5602 ZA Eindhoven, the Netherlands.
J Vasc Surg. 2006 Jun;43(6):1111-1123; discussion 1123. doi: 10.1016/j.jvs.2006.01.035.
To understand the potential of endovascular aneurysm repair (EVAR) in patients presenting with a ruptured abdominal aortic aneurysm (rAAA), the proportion in whom this procedure was applicable was assessed. Mortality and morbidity was also determined in patients treated with emergency EVAR (eEVAR) when anatomic and hemodynamic conditions allowed (ie, in the entire cohort with patients receiving endovascular and open repair combined). In addition, a comparison was made between the treatment group with eEVAR and open repair.
Between February 2003 and September 2004, 10 participating institutions enrolled a representative sample of 100 consecutive patients in whom eEVAR was considered. Patients in the New Endograft treatment in Ruptured abdominal aortic Aneurysm (ERA) trial were offered eEVAR or open repair in accordance with their clinical condition or anatomic configuration. Written informed consent was obtained from all patients or their legal representatives. The study included patients who were treated by stent-graft technique or by open surgery in the case of adverse anatomy for endoluminal stent-grafting or severe hemodynamic instability, or both. Data were collated in a centralized database for analysis. The study was sponsored and supported by Medtronic, and eEVAR was uniquely performed with a Talent aortouniiliac (AUI) system in all patients. Crude and adjusted 30-day or in-hospital and 3-month mortality rates were assessed for the entire group as a whole and the EVAR and open repair category separately. Complication rates were also assessed.
Stent-graft repair was performed in 49 patients and open surgery in 51. No significant differences were observed between these treatment groups with regard to comorbidity at presentation, hemodynamic instability, and the proportion of patients who could be assessed by preoperative computed tomography scanning. Patients with eEVAR more frequently demonstrated a suitable infrarenal neck for endovascular repair, a longer infrarenal neck, and suitable iliac arteries for access than patients with open repair. The primary reason to perform open aneurysm repair was an unfavorable configuration of the neck in 80% of the patients. In patients undergoing eEVAR, operative blood loss was less, intensive care admission time was shorter, and the duration of mechanical ventilation was shorter (P < or = .02, all comparisons). The 30-day or in-hospital mortality was 35% in the eEVAR category, 39% in patients with open repair, and 37% overall. There was no statistically significant difference between the treatment groups with regard to crude mortality rates or rates adjusted for age, gender, hemodynamic shock, and pre-existent pulmonary disease. The cumulative 3-month all-cause mortality was 40% in the eEVAR group and 42% in the open repair group (no significant differences at crude and adjusted comparisons). The 3-month primary complication rate in the two treatment groups was similar at 59%.
In approximately half the rAAA patients, eEVAR appeared viable. An unsuitable infrarenal neck was the most frequent cause to select open repair. In dedicated centers using a Talent AUI system, eEVAR appeared to be a feasible method for treatment of a rAAA. The overall first-month mortality did not differ across treatment groups (patients with endovascular and open repair combined), yet was somewhat lower than observed in a recent meta-analysis reporting on open repair.
为了解血管腔内修复术(EVAR)在腹主动脉瘤破裂(rAAA)患者中的应用潜力,评估了该手术适用患者的比例。当解剖和血流动力学条件允许时(即,在接受血管腔内修复和开放修复的所有患者组成的整个队列中),还确定了接受急诊EVAR(eEVAR)治疗患者的死亡率和发病率。此外,对接受eEVAR治疗组和开放修复组进行了比较。
在2003年2月至2004年9月期间,10个参与机构纳入了100例连续的有代表性患者样本,这些患者被认为适合接受eEVAR治疗。腹主动脉瘤破裂新型血管内移植物治疗(ERA)试验中的患者根据其临床状况或解剖结构接受eEVAR或开放修复。所有患者或其法定代表人均签署了书面知情同意书。该研究纳入了采用支架移植物技术治疗的患者,以及因腔内支架移植物植入的解剖结构不利或严重血流动力学不稳定,或两者兼而有之而接受开放手术的患者。数据汇总到一个中央数据库进行分析。该研究由美敦力公司赞助和支持,所有患者均仅使用Talent主动脉单髂动脉(AUI)系统进行eEVAR治疗。对整个组以及EVAR组和开放修复组分别评估了粗死亡率和校正后的30天或住院期间及3个月死亡率。还评估了并发症发生率。
49例患者接受了支架移植物修复,51例接受了开放手术。这些治疗组在就诊时的合并症、血流动力学不稳定以及术前计算机断层扫描可评估患者的比例方面未观察到显著差异。与接受开放修复的患者相比,接受eEVAR治疗的患者更常表现出适合血管腔内修复的肾下颈部、更长的肾下颈部以及适合入路的髂动脉。进行开放动脉瘤修复的主要原因是80%的患者颈部结构不利。接受eEVAR治疗的患者术中失血量更少、重症监护病房住院时间更短、机械通气时间更短(所有比较,P≤0.02)。eEVAR组的30天或住院期间死亡率为35%,开放修复组为39%,总体为37%。在粗死亡率或根据年龄、性别、血流动力学休克和既往肺部疾病校正的死亡率方面,治疗组之间无统计学显著差异。eEVAR组3个月累计全因死亡率为40%,开放修复组为42%(粗死亡率和校正后比较均无显著差异)。两个治疗组3个月的主要并发症发生率相似,均为59%。
在大约一半的rAAA患者中,eEVAR似乎是可行的。肾下颈部不合适是选择开放修复最常见的原因。在使用Talent AUI系统的专业中心,eEVAR似乎是治疗rAAA的一种可行方法。各治疗组(血管腔内修复和开放修复患者合并)的总体首月死亡率无差异,但略低于近期一项关于开放修复的荟萃分析中观察到的死亡率。